Published in Oncogene on May 05, 2014
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov (2015) 1.64
MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells. Oncotarget (2015) 0.84
LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. J Clin Invest (2015) 0.82
Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas. Oncotarget (2015) 0.82
miRNA-337-3p inhibits gastric cancer progression through repressing myeloid zinc finger 1-facilitated expression of matrix metalloproteinase 14. Oncotarget (2016) 0.80
Genome-scale long noncoding RNA expression pattern in squamous cell lung cancer. Sci Rep (2015) 0.80
MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells. Oncotarget (2016) 0.78
DNA methylation promotes paired box 2 expression via myeloid zinc finger 1 in endometrial cancer. Oncotarget (2016) 0.77
Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo. Oncotarget (2015) 0.77
AKT1, LKB1, and YAP1 revealed as MYC interactors with NanoLuc-based protein-fragment complementation assay. Mol Pharmacol (2017) 0.75
The Mutational Landscape of the Oncogenic MZF1 SCAN Domain in Cancer. Front Mol Biosci (2016) 0.75
c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma. Oncotarget (2016) 0.75
Farnesiferol c induces apoptosis via regulation of L11 and c-Myc with combinational potential with anticancer drugs in non-small-cell lung cancers. Sci Rep (2016) 0.75
Discovery of a Family of Genomic Sequences Which Interact Specifically with the c-MYC Promoter to Regulate c-MYC Expression. PLoS One (2016) 0.75
Long-term persistent infection of HPV 16 E6 up-regulate SP1 and hTERT by inhibiting LKB1 in lung cancer cells. PLoS One (2017) 0.75
miR-200b inhibits CD133(+) glioma cells by targeting the AKT pathway. Oncol Lett (2017) 0.75
c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. Oncogene (2014) 0.87
LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas. Oncogene (2013) 0.86
Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer. Cell Death Differ (2014) 0.83
TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells. Cell Death Dis (2016) 0.75